Advances in melanoma therapy.
This review discusses several advances in melanoma therapy that have recently occurred or are presently in a developmental stage. We discuss the history and present dogma regarding assessment of the regional lymph nodes and adjuvant therapy for melanoma. Of special interest is radiolymphatic sentinel node mapping of the lymph nodes and adjuvant interferon alfa-2b for thick primary lesions and stage III disease. We also discuss several evolving novel and innovative genetic immunotherapy approaches for patients with stage IV disease.
Johnson
T M
TM
Department of Dermatology, University of Michigan Medical Center, Ann Arbor, USA.
Yahanda
A M
AM
Chang
A E
AE
Fader
D J
DJ
Sondak
V K
VK
D017024:Chemotherapy, Adjuvant; D005821:Genetic Techniques; D006801:Humans; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D009367:Neoplasm Staging; D015642:Radiology, Interventional; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins; D012394:Rosaniline Dyes; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D012394:Rosaniline Dyes; C025484:iso-sulfan blue